Target
VSIG4
2 abstracts
Abstract
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, CHA University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer.Org: Eutilex Co., Ltd., Samsung Medical Center, Sungkyunkwan University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,